Elvina Almuradova: It’s Not Just About Better Drugs – Tumor Biology Matters

Elvina Almuradova, Ambassador at European School of Oncology, shared on X about a recent paper by A. Papakonstantinou et al. published in ESMO Annals of Oncology:

“In HER2+ BC, ADCs are promising, but it’s not just about better drugs – tumor biology matters. As T-DXd rises, we must still protect early-stage patients from ILD. Time to focus on personalization.”